Differences in the prevalence of uveitis between Crohn's disease and ulcerative colitis: A systematic review and meta‐analysis

Lin, Haowen; Zhang, Jiaqing; Liang, Chen; Wu, Dongxuan; Tan, Yuan; Luo, Lixia; Liu, Zhenzhen

doi:10.1111/aos.15793

Cited by 4 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent systematic review and meta-analyses reported an uveitis prevalence of 2.38% in IBD patients. Uveitis was statistically significantly more prevalent in CD (3.27%) than in UC patients (1.60%, p < 0.05) [17,61]. While CU's activity and uveitis do not correlate, uveitis is much more frequent and persistent during CD flares [62].…”

Section: Uveitismentioning

confidence: 91%

Ophthalmological Manifestations in Inflammatory Bowel Diseases: Keep an Eye on It

Migliorisi,

Vella,

Dal Buono

et al. 2024

Cells

View full text Add to dashboard Cite

Background and aims: Inflammatory bowel diseases (IBD) are multifactorial chronic inflammatory disorders affecting the gastrointestinal tract. However, a broad spectrum of extraintestinal manifestations (EIMs) is associated with IBD, affecting several organs and systems, such as the skin, musculoskeletal and hepatobiliary systems, and, not least, the eye. Approximately 10% of IBD patients can develop ocular EIMs (O-EIMs) with a higher prevalence in Crohn’s disease (CD). Eye-redness, photophobia, pain, and blurred vision are the common symptoms, with a wide rate of severity and clinical impact on the quality of life. This narrative review aims to summarize the prevalence, pathogenesis, and current evidence-based management of O-EIMs, underlying the importance of a holistic approach and specialties collaboration for a prompt diagnosis and treatment. Methods: PubMed was searched up to December 2023 to identify relevant studies investigating the pathogenesis, epidemiology, and treatment of O-EIMs in IBD patients. Results: The mechanisms underlying O-EIMs are partially unknown, encompassing immune dysregulation, shared antigens between the eye and the gut, genetic predisposition, and systemic inflammation driven by high levels of interleukins and cytokines in IBD patients. The complexity of O-EIMs’ pathogenesis reflects in the management of these conditions, varying from topical and systemic steroids to immunomodulatory molecules and biologic therapy, such as anti-tumor necrosis factor (TNF)-alpha. A multidisciplinary approach is the backbone of the management of O-EIMs.

show abstract

Section: Uveitismentioning

confidence: 91%

Ophthalmological Manifestations in Inflammatory Bowel Diseases: Keep an Eye on It

Migliorisi,

Vella,

Dal Buono

et al. 2024

Cells

View full text Add to dashboard Cite

show abstract

Application of Polymers as Drug Nanocarriers in the Oral Treatment of Ulcerative Colitis

Liu,

Huang,

et al. 2024

ChemistrySelect

View full text Add to dashboard Cite

Ulcerative colitis (UC) is a chronic non‐specific inflammatory disease of the intestines with a high prevalence. Polymer‐prepared nanoparticles are well‐targeted, highly biocompatible, and have high potential for personalized therapy. Polymer nanoparticles are able to achieve localized therapy through their unique design. First, this review compares the advantages and disadvantages of natural and synthetic polymeric materials as well as describes the application of polymeric nanoparticles in UC therapy. Then, the preparation, characterization methods, and current challenges of common polymer nanoparticles are presented. Next, one‐by‐one examples of polymer nanoparticle‐targeted drug delivery strategies for the treatment of UC are presented. In addition, polymer nanoparticle‐based therapeutic approaches for UC, including anti‐inflammatory therapies, reactive oxygen species scavenging therapies, and intestinal flora modulation therapies, are presented. Finally, future research directions for polymer nanoparticles in UC therapy are discussed and current challenges are identified. The aim of this paper is to provide valuable references and guidance for researchers to design and develop novel UC therapies.

show abstract

Ocular Manifestations of IBD: Pathophysiology, Epidemiology, and Iatrogenic Associations of Emerging Treatment Strategies

Richardson,

Yoon,

Moussa

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a complex, multisystemic disease and is associated with ocular pathology in 4–12% of patients. In general, ocular disease affects Crohn’s patients more frequently than those with ulcerative colitis. Episcleritis and uveitis are the most common presentations, with episcleritis often correlating with IBD flares, whereas uveitis presents independently of IBD activity and, in some cases, may even alert clinicians to a new diagnosis of IBD. Corneal EIMs encompass a range of pathologies, such as the common and benign keratoconjunctivitis sicca (dry eye disease), which nevertheless causes significant patient discomfort, and the rarer condition of peripheral ulcerative keratitis, which warrants urgent review due to the risk of corneal perforation. Alongside EIMs, clinicians should also be aware of the iatrogenic consequences to the eye following treatment of IBD. Corticosteroids may cause cataracts, glaucoma, and—indirectly via hyperglycaemia—diabetic retinopathy. Methotrexate is irritating to ocular tissues and may cause conjunctivitis and blepharitis. Biologic medications, such as anti-TNFα agents, overlap in their use as treatment of both IBD and uveitis, and yet in some patients may also increase the risk of acute uveitis flares, as well as opportunistic, sight-threatening infections. With integrated care between gastroenterology and ophthalmology, patient outcomes can be improved by facilitating earlier detection and management of ocular disease. This narrative review summarises the ocular extraintestinal manifestations of IBD, including pathophysiology, epidemiology, and current treatment strategies.

show abstract

Differences in the prevalence of uveitis between Crohn's disease and ulcerative colitis: A systematic review and meta‐analysis

Cited by 4 publications

References 38 publications

Ophthalmological Manifestations in Inflammatory Bowel Diseases: Keep an Eye on It

Ophthalmological Manifestations in Inflammatory Bowel Diseases: Keep an Eye on It

Application of Polymers as Drug Nanocarriers in the Oral Treatment of Ulcerative Colitis

Ocular Manifestations of IBD: Pathophysiology, Epidemiology, and Iatrogenic Associations of Emerging Treatment Strategies

Contact Info

Product

Resources

About